These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22822338)

  • 1. The role of positron emission tomography in colorectal carcinoma.
    Nachar OM
    Ochsner J; 2002; 4(3):146-55. PubMed ID: 22822338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of pre-and postoperative 18F-FDG PET/CT in patients undergoing liver transplantation for hepatocellular carcinoma.
    Wang XL; Li H; Wang QS; Zhang XL
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1087-91, 1095. PubMed ID: 16939890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
    Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
    Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study.
    Musholt TJ; Musholt PB; Dehdashti F; Moley JF
    Surgery; 1997 Dec; 122(6):1049-60; discussion 1060-1. PubMed ID: 9426419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
    Gerbaudo VH; Mamede M; Trotman-Dickenson B; Hatabu H; Sugarbaker DJ
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of PET in the diagnosis and staging of lung cancer.
    Coates G; Skehan SJ
    Can Respir J; 1999; 6(2):145-52. PubMed ID: 10322097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
    Kumar R; Hawkins RA; Yeh BM; Wang ZJ
    Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography imaging of brain tumors.
    Wong TZ; van der Westhuizen GJ; Coleman RE
    Neuroimaging Clin N Am; 2002 Nov; 12(4):615-26. PubMed ID: 12687915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
    Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
    Graeber GM; Gupta NC; Murray GF
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity.
    Schillaci O
    Semin Nucl Med; 2012 Jul; 42(4):267-80. PubMed ID: 22681676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET imaging in breast cancer.
    Bombardieri E; Crippa F
    Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of chest masses by FDG positron emission tomography.
    Hübner KF; Buonocore E; Singh SK; Gould HR; Cotten DW
    Clin Nucl Med; 1995 Apr; 20(4):293-8. PubMed ID: 7788982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
    Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
    J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET scanning in the diagnosis of gastrointestinal cancers.
    van Kouwen MC; Oyen WJ; Nagengast FM; Jansen JB; Drenth JP
    Scand J Gastroenterol Suppl; 2004; (241):85-92. PubMed ID: 15696855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.